Tag: nyse:ast

January 24, 2019

Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...
September 12, 2018

Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...
July 12, 2018

Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...